April 22, 2024

Global Innovation Summit 2026

Global Innovation Summit 2026

Welcome to the Global Innovation Summit!

The Global Innovation Summit 2026 is your opportunity to kick off your innovation project with international partners, strengthen your business and explore suitable funding opportunities in over 40 countries.

The one-day event will take place on Wednesday, 6 May 2026 at Messe Basel, Switzerland.

Why attend the Global Innovation Summit 2026?

The Global Innovation Summit is a recurring gathering organised in the framework of Eureka the world’s largest network for supporting collaborative innovation.

The 2026 edition is organised by the Swiss Eureka Chair represented by Innosuisse and focuses on innovation in the biotech industry combined with enabling technologies and services like digitalisation, translational research and development, chemistry, manufacturing, control and quality control processes, etc.

It will feature an international public, inspiring keynotes and a strong focus on matchmaking for international projects. With a thousand participants expected, the Summit offers a unique chance to turn your ideas into action on a global scale.

The Global Innovation Summit runs back-to-back with the annual Swiss Biotech Day and aims at linking the Swiss biotech ecosystem with global businesses and science to strengthen international cooperation.

  • 🌍 Explore international collaboration.
  • 🤝 Make meaningful connections for project funding.
  • 🎤 Learn from industry leaders.
  • 💡 Get inspired.
  • 🚀 Stay ahead of the curve.
  • 🎉 Enjoy the experience.
  • ✨ Attend free of charge.

Take the opportunity to connect, exchange ideas and collaborate. Register now!

register now

Our latest News

discover more
Member2Member: Where expertise meets the community

Member2Member: Where expertise meets the community

Every company in the bioRN network has a story to tell. More importantly, every company has knowledge that can help others move faster, avoid mistakes and spark new collaborations. That is the idea behind bioRN’s Member2Member series. Instead of traditional company presentations, Member2Member opens the doors to our member organisations and puts their expertise centre […]

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp